DNMT3B sirna

DNMT3B siRNA (Human)

Cat. Num. AAA8210268

• Gene Names: DNMT3B; ICF; ICF1; M.HsaIIIB
• Reactivity: Human
• Applications: RNA Interference (RNAi)
• Purity: > 97%
• Synonyms: DNMT3B; DNMT3B siRNA (Human); DNA; cytosine-5)-methyltransferase 3B; Dnmt3b; DNA methyltransferase HsaIIIB; DNA MTase HsaIIIB; M.HsaIIIB; DNMT3B sirna

• Host: Synthetic
• Reactivity: Human
• Specificity: DNMT3B siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
• Purity/Purification: > 97%
• Form/Format: Lyophilized powder
• Sequence Length: 728

• Applicable Applications for DNMT3B sirna: RNA Interference (RNAi)
• Quality Control: Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
• Directions for Use: We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
• Components: We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human DNMT3B gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
• Preparation and Storage: Shipped at 4 degree C. Store at -20 degree C for one year.

Related Product Information for DNMT3B sirna

siRNA to inhibit DNMT3B expression using RNA interference

NCBI and Uniprot Product Information

• NCBI GI #: 333440487
• NCBI GeneID: 1789
• NCBI Accession #: NP_001193984.1
• NCBI GenBank Nucleotide #: NM_001207055.1
• UniProt Accession #: Q9UBC3; Q9UBD4; Q9UJQ5; Q9UKA6; Q9UNE5; A2A2E2; B4DSM8; B4DSU1; E1P5M6; E1P5M7; E7EN63; E9PBF2
• Molecular Weight: 81,311 Da
• NCBI Official Full Name: DNA (cytosine-5)-methyltransferase 3B isoform 7
• NCBI Official Synonym Full Names: DNA (cytosine-5-)-methyltransferase 3 beta
• NCBI Official Symbol: DNMT3B
• NCBI Official Synonym Symbols: ICF; ICF1; M.HsaIIIB
• NCBI Protein Information: DNA (cytosine-5)-methyltransferase 3B
• UniProt Protein Name: DNA (cytosine-5)-methyltransferase 3B
• Protein Family: DNA
• UniProt Gene Name: DNMT3B
• UniProt Synonym Gene Names: Dnmt3b; DNA MTase HsaIIIB; M.HsaIIIB
• UniProt Entry Name: DNM3B_HUMAN

NCBI Description

CpG methylation is an epigenetic modification that is important for embryonic development, imprinting, and X-chromosome inactivation. Studies in mice have demonstrated that DNA methylation is required for mammalian development. This gene encodes a DNA methyltransferase which is thought to function in de novo methylation, rather than maintenance methylation. The protein localizes primarily to the nucleus and its expression is developmentally regulated. Mutations in this gene cause the immunodeficiency-centromeric instability-facial anomalies (ICF) syndrome. Eight alternatively spliced transcript variants have been described. The full length sequences of variants 4 and 5 have not been determined. [provided by RefSeq, May 2011]

Uniprot Description

DNMT3B: a ubiquitous DNA methyltransferase required for genome wide de novo methylation and essential for development. DNA methylation is coordinated with methylation of histones. Numerous cancer cell lines and primary acute leukemias express aberrant DNMT3B transcripts, especially DNMT3B7. Transfection of DNMT3B7 into 293 cells alters the pattern of genes expressed in the transfected cells. Can interact with DNMT1, which might be a co-operative event during DNA methylation. Methylates CpG sites at a rate slower than DNMT3A and much slower than DNMT1. Interacts with SUV39H1, SETDB1, SUMO1 and UBE2I9. Interacts with DNMT1 and DNMT3A. Mutations in DNMT3B have been shown to cause immunodeficiency-centromeric instability-facial anomalies syndrome (ICF). Six alternatively spliced isoforms of the human protein have been reported. Isoform 1 is expressed in all tissues except brain, skeletal muscle and PBMC, 3 is ubiquitous, 4 is expressed in all tissues except brain, skeletal muscle, lung and prostate and 5 is detectable only in testis and at very low level in brain and prostate. Isoforms 4 and 5 are probably not enzymatically active due to the deletion of two conserved methyltransferase motifs.

Protein type: Methyltransferase, DNA; Methyltransferase; Amino Acid Metabolism - cysteine and methionine; EC 2.1.1.37; Cell development/differentiation

Chromosomal Location of Human Ortholog: 20q11.2

Cellular Component: nucleoplasm; intracellular membrane-bound organelle; cytoplasm; nuclear heterochromatin; nucleus

Molecular Function: DNA (cytosine-5-)-methyltransferase activity; protein binding; unmethylated CpG binding; DNA (cytosine-5-)-methyltransferase activity, acting on CpG substrates; metal ion binding; transcription corepressor activity; DNA-methyltransferase activity

Biological Process: response to drug; negative regulation of histone H3-K9 methylation; genetic imprinting; S-adenosylhomocysteine metabolic process; negative regulation of transcription from RNA polymerase II promoter; positive regulation of histone H3-K4 methylation; regulation of gene expression, epigenetic; cytosine methylation within a CG sequence; protein complex localization; methylation-dependent chromatin silencing; negative regulation of gene expression, epigenetic; DNA methylation; S-adenosylmethioninamine metabolic process; gene expression; response to ionizing radiation; positive regulation of neuron differentiation; DNA methylation on cytosine

Disease: Immunodeficiency-centromeric Instability-facial Anomalies Syndrome 1